Literature DB >> 22865774

A conditional error function approach for subgroup selection in adaptive clinical trials.

T Friede1, N Parsons, N Stallard.   

Abstract

Growing interest in personalised medicine and targeted therapies is leading to an increase in the importance of subgroup analyses. If it is planned to view treatment comparisons in both a predefined subgroup and the full population as co-primary analyses, it is important that the statistical analysis controls the familywise type I error rate. Spiessens and Debois (Cont. Clin. Trials, 2010, 31, 647-656) recently proposed an approach specific for this setting, which incorporates an assumption about the correlation based on the known sizes of the different groups, and showed that this is more powerful than generic multiple comparisons procedures such as the Bonferroni correction. If recruitment is slow relative to the length of time taken to observe the outcome, it may be efficient to conduct an interim analysis. In this paper, we propose a new method for an adaptive clinical trial with co-primary analyses in a predefined subgroup and the full population based on the conditional error function principle. The methodology is generic in that we assume test statistics can be taken to be normally distributed rather than making any specific distributional assumptions about individual patient data. In a simulation study, we demonstrate that the new method is more powerful than previously suggested analysis strategies. Furthermore, we show how the method can be extended to situations when the selection is not based on the final but on an early outcome. We use a case study in a targeted therapy in oncology to illustrate the use of the proposed methodology with non-normal outcomes.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22865774     DOI: 10.1002/sim.5541

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

Review 1.  Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Authors:  Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2015-03-05       Impact factor: 2.872

2.  Using Bayesian modeling in frequentist adaptive enrichment designs.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

Review 3.  Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.

Authors:  Ciara Nugent; Wentian Guo; Peter Müller; Yuan Ji
Journal:  JCO Precis Oncol       Date:  2019-10-24

4.  Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models.

Authors:  Ganggang Xu; Huirong Zhu; J Jack Lee
Journal:  Comput Stat Data Anal       Date:  2020-04       Impact factor: 1.681

5.  Optimal decision rules for biomarker-based subgroup selection for a targeted therapy in oncology.

Authors:  Johannes Krisam; Meinhard Kieser
Journal:  Int J Mol Sci       Date:  2015-05-07       Impact factor: 5.923

6.  Subgroup detection and sample size calculation with proportional hazards regression for survival data.

Authors:  Suhyun Kang; Wenbin Lu; Rui Song
Journal:  Stat Med       Date:  2017-08-08       Impact factor: 2.373

7.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

8.  Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.

Authors:  Olga Marchenko; Valerii Fedorov; J Jack Lee; Christy Nolan; José Pinheiro
Journal:  Ther Innov Regul Sci       Date:  2013-11-26       Impact factor: 1.778

Review 9.  Clinical trial designs incorporating predictive biomarkers.

Authors:  Lindsay A Renfro; Himel Mallick; Ming-Wen An; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Cancer Treat Rev       Date:  2016-01-05       Impact factor: 12.111

10.  Auxiliary variable-enriched biomarker-stratified design.

Authors:  Ting Wang; Xiaofei Wang; Haibo Zhou; Jianwen Cai; Stephen L George
Journal:  Stat Med       Date:  2018-09-16       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.